Abstract:
Endothelial cells (ECs) are widely distributed in the human body and play crucial roles in the circulatory and immune systems. ECs dysfunction contributes to the progression of various chronic cardiovascular, renal, and metabolic diseases. As a key transcription factor in ECs, FLI-1 is involved in the differentiation, migration, proliferation, angiogenesis and blood coagulation of ECs. Imbalanced FLI-1 expression in ECs can lead to various diseases. Low FLI-1 expression leads to systemic sclerosis by promoting fibrosis and vascular lesions, to pulmonary arterial hypertension by promoting a local inflammatory state and vascular lesions, and to tumour metastasis by promoting the EndMT process. High FLI-1 expression leads to lupus nephritis by promoting a local inflammatory state. Therefore, FLI-1 in ECs may be a good target for the treatment of the abovementioned diseases. This comprehensive review provides the first overview of FLI-1-mediated regulation of ECs processes, with a focus on its influence on the abovementioned diseases and existing FLI-1-targeted drugs. A better understanding of the role of FLI-1 in ECs may facilitate the design of more effective targeted therapies for clinical applications, particularly for tumour treatment.
摘要:
内皮细胞(ECs)广泛分布于人体,在循环系统和免疫系统中起着至关重要的作用。ECs功能障碍有助于各种慢性心血管疾病的进展,肾,和代谢性疾病。作为ECs中的关键转录因子,FLI-1参与分化,迁移,扩散,血管生成和内皮细胞的凝血。ECs中FLI-1表达失衡可导致多种疾病。低FLI-1表达通过促进纤维化和血管病变导致系统性硬化症,通过促进局部炎症状态和血管病变来治疗肺动脉高压,并通过促进EndMT过程进行肿瘤转移。高FLI-1表达通过促进局部炎症状态导致狼疮性肾炎。因此,ECs中的FLI-1可能是治疗上述疾病的良好靶点。这篇全面的综述首次概述了FLI-1介导的ECs过程调控,重点关注其对上述疾病和现有FLI-1靶向药物的影响。更好地了解FLI-1在ECs中的作用可能有助于设计更有效的临床应用靶向疗法。特别是肿瘤治疗。